Possible changes in the standard of care for metastatic and non-metastatic prostate cancer
Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer
De-escalated treatment improves the management of stage IIA/B seminoma
Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy
Cautious optimism for new ICI-based combinations in mCRPC treatment
Early-phase studies, COSMIC-021 and CheckMate 9KD, show promising results in men with prostate cancer, but patient selection is key